Protara Therapeutics (TARA) CFO receives new RSUs and 175,000 options

Rhea-AI Filing Summary

Protara Therapeutics Chief Financial Officer Patrick Fabbio reported new equity awards in the company. On January 16, 2026, he received 28,000 shares of common stock at a price of $0, issued as restricted stock units. These RSUs vest in three equal installments on the first, second and third anniversaries of January 16, 2026, as long as he remains in continuous service. After this grant, he directly beneficially owned 70,439 shares of common stock.

On the same date, he was also granted 175,000 stock options with an exercise price of $5.01 per share. For these options, 25% vest on the one-year anniversary of January 16, 2026, and the remaining portion vests in equal monthly installments over the following three years, also conditioned on continued service. Following this grant, he directly held 175,000 stock options in total.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Fabbio Patrick

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	175,000	$0.00	--
Grant/Award	Common Stock	28,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 175,000 shares (Direct); Common Stock — 70,439 shares (Direct)

Footnotes (1)

1. The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fabbio Patrick

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		A		28,000(1)	A	$0	70,439	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.01	01/16/2026		A		175,000		(2)	01/15/2036	Common Stock	175,000	$0	175,000	D

Explanation of Responses:

1. The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.

2. 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Remarks:

	/s/ Patrick Fabbio	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did TARA CFO Patrick Fabbio receive on January 16, 2026?

On January 16, 2026, TARA CFO Patrick Fabbio received 28,000 restricted stock units (RSUs) of common stock and 175,000 stock options with an exercise price of $5.01 per share.

How do the new RSUs granted to TARA CFO vest?

The 28,000 RSUs granted to the TARA CFO vest in three equal one-third installments on the first, second and third anniversaries of January 16, 2026, subject to his continuous service with the company.

What is the vesting schedule for the 175,000 stock options reported by TARA?

For the 175,000 stock options, 25% vest on the one-year anniversary of January 16, 2026, and the remaining shares vest in 1/48th monthly installments over the next three years, contingent on continuous service.

What is the exercise price of the stock options granted to the TARA CFO?

The stock options granted to the TARA CFO have an exercise price of $5.01 per share, as disclosed in the derivative securities table.

How many TARA common shares does the CFO own after the reported RSU grant?

After the 28,000-share RSU grant, the TARA CFO directly and beneficially owns 70,439 shares of the company’s common stock.

Are the reported TARA equity awards dependent on continued employment?

Yes. Both the RSUs and stock options vest only if the Reporting Person maintains continuous service with Protara Therapeutics through each vesting date.